RFG Advisory’s Avadel Pharmaceuticals AVDL Stock Holding History

RFG Advisory’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-73,944	Closed	-$1.13M	–	983
2025 Q3	$1.13M	Buy	+73,944	New	+$962K	0.02%	463

Other funds holding AVDL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RFG Advisory's AVDL Position: Q4 2025 in Review

RFG Advisory sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 73,944 shares — an estimated $1.13M sold.

RFG Advisory first reported a position in AVDL in Q3 2025 and held it in 1 quarter. The position peaked at $1.13M in Q3 2025. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

RFG Advisory reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
RFG Advisory sold 73,944 Avadel Pharmaceuticals shares in Q4 2025, an estimated $1.13M.
RFG Advisory first reported a position in Avadel Pharmaceuticals in Q3 2025 and held it in 1 quarter.
RFG Advisory's Avadel Pharmaceuticals position peaked at $1.13M in Q3 2025.
207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on RFG Advisory's 13F filing for Q4 2025, filed 3 Feb 2026.